435 related articles for article (PubMed ID: 27897048)
41. Development of Inducible CD19-CAR T Cells with a Tet-On System for Controlled Activity and Enhanced Clinical Safety.
Gu X; He D; Li C; Wang H; Yang G
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400287
[TBL] [Abstract][Full Text] [Related]
42. Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies.
Poirot L; Philip B; Schiffer-Mannioui C; Le Clerre D; Chion-Sotinel I; Derniame S; Potrel P; Bas C; Lemaire L; Galetto R; Lebuhotel C; Eyquem J; Cheung GW; Duclert A; Gouble A; Arnould S; Peggs K; Pule M; Scharenberg AM; Smith J
Cancer Res; 2015 Sep; 75(18):3853-64. PubMed ID: 26183927
[TBL] [Abstract][Full Text] [Related]
43. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.
Rodgers DT; Mazagova M; Hampton EN; Cao Y; Ramadoss NS; Hardy IR; Schulman A; Du J; Wang F; Singer O; Ma J; Nunez V; Shen J; Woods AK; Wright TM; Schultz PG; Kim CH; Young TS
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E459-68. PubMed ID: 26759369
[TBL] [Abstract][Full Text] [Related]
44. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
45. CD19 chimeric antigen receptor T cell therapy for the treatment of B cell lineage acute lymphoblastic leukemia.
Chen R; Song XT; Chen B
Discov Med; 2015 Oct; 20(110):185-90. PubMed ID: 26562471
[TBL] [Abstract][Full Text] [Related]
46. Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture.
Tyagarajan S; Schmitt D; Acker C; Rutjens E
Cytotherapy; 2019 Dec; 21(12):1198-1205. PubMed ID: 31837735
[TBL] [Abstract][Full Text] [Related]
47. Building blocks for institutional preparation of CTL019 delivery.
McGuirk J; Waller EK; Qayed M; Abhyankar S; Ericson S; Holman P; Keir C; Myers GD
Cytotherapy; 2017 Sep; 19(9):1015-1024. PubMed ID: 28754600
[TBL] [Abstract][Full Text] [Related]
48. Driving CAR T-cells forward.
Jackson HJ; Rafiq S; Brentjens RJ
Nat Rev Clin Oncol; 2016 Jun; 13(6):370-83. PubMed ID: 27000958
[TBL] [Abstract][Full Text] [Related]
49. Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells.
Levine BL
Cancer Gene Ther; 2015 Mar; 22(2):79-84. PubMed ID: 25675873
[TBL] [Abstract][Full Text] [Related]
50. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.
Kebriaei P; Singh H; Huls MH; Figliola MJ; Bassett R; Olivares S; Jena B; Dawson MJ; Kumaresan PR; Su S; Maiti S; Dai J; Moriarity B; Forget MA; Senyukov V; Orozco A; Liu T; McCarty J; Jackson RN; Moyes JS; Rondon G; Qazilbash M; Ciurea S; Alousi A; Nieto Y; Rezvani K; Marin D; Popat U; Hosing C; Shpall EJ; Kantarjian H; Keating M; Wierda W; Do KA; Largaespada DA; Lee DA; Hackett PB; Champlin RE; Cooper LJ
J Clin Invest; 2016 Sep; 126(9):3363-76. PubMed ID: 27482888
[TBL] [Abstract][Full Text] [Related]
51. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
Kochenderfer JN; Wilson WH; Janik JE; Dudley ME; Stetler-Stevenson M; Feldman SA; Maric I; Raffeld M; Nathan DA; Lanier BJ; Morgan RA; Rosenberg SA
Blood; 2010 Nov; 116(20):4099-102. PubMed ID: 20668228
[TBL] [Abstract][Full Text] [Related]
52. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.
Fraietta JA; Nobles CL; Sammons MA; Lundh S; Carty SA; Reich TJ; Cogdill AP; Morrissette JJD; DeNizio JE; Reddy S; Hwang Y; Gohil M; Kulikovskaya I; Nazimuddin F; Gupta M; Chen F; Everett JK; Alexander KA; Lin-Shiao E; Gee MH; Liu X; Young RM; Ambrose D; Wang Y; Xu J; Jordan MS; Marcucci KT; Levine BL; Garcia KC; Zhao Y; Kalos M; Porter DL; Kohli RM; Lacey SF; Berger SL; Bushman FD; June CH; Melenhorst JJ
Nature; 2018 Jun; 558(7709):307-312. PubMed ID: 29849141
[TBL] [Abstract][Full Text] [Related]
53. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.
Geyer MB; Brentjens RJ
Cytotherapy; 2016 Nov; 18(11):1393-1409. PubMed ID: 27592405
[TBL] [Abstract][Full Text] [Related]
54. Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor.
Singh H; Moyes JS; Huls MH; Cooper LJ
Cancer Gene Ther; 2015 Mar; 22(2):95-100. PubMed ID: 25591810
[TBL] [Abstract][Full Text] [Related]
55. Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma.
Avanzi MP; Brentjens RJ
J Natl Compr Canc Netw; 2017 Nov; 15(11):1429-1437. PubMed ID: 29118234
[TBL] [Abstract][Full Text] [Related]
56. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
Luskin MR; DeAngelo DJ
Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
[TBL] [Abstract][Full Text] [Related]
57. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.
Ruella M; Xu J; Barrett DM; Fraietta JA; Reich TJ; Ambrose DE; Klichinsky M; Shestova O; Patel PR; Kulikovskaya I; Nazimuddin F; Bhoj VG; Orlando EJ; Fry TJ; Bitter H; Maude SL; Levine BL; Nobles CL; Bushman FD; Young RM; Scholler J; Gill SI; June CH; Grupp SA; Lacey SF; Melenhorst JJ
Nat Med; 2018 Oct; 24(10):1499-1503. PubMed ID: 30275568
[TBL] [Abstract][Full Text] [Related]
58. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
Singh N; Frey NV; Grupp SA; Maude SL
Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
[TBL] [Abstract][Full Text] [Related]
59. Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.
Ruella M; June CH
Curr Hematol Malig Rep; 2016 Oct; 11(5):368-84. PubMed ID: 27475429
[TBL] [Abstract][Full Text] [Related]
60. Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.
Qin L; Lai Y; Zhao R; Wei X; Weng J; Lai P; Li B; Lin S; Wang S; Wu Q; Liang Q; Li Y; Zhang X; Wu Y; Liu P; Yao Y; Pei D; Du X; Li P
J Hematol Oncol; 2017 Mar; 10(1):68. PubMed ID: 28288656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
